Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Neurology

Background:

• Epilepsy management during pregnancy requires careful drug monitoring.
• Primidone is an antiepileptic drug metabolized to phenobarbitone.
• Changes in drug metabolism during pregnancy can affect therapeutic efficacy and safety.

Purpose of the Study:

• To investigate the pharmacokinetic changes of primidone and its metabolite phenobarbitone during pregnancy.
• To assess the impact of pregnancy on plasma concentrations of primidone and phenobarbitone.
• To evaluate the need for therapeutic drug monitoring in pregnant epileptic patients.

Main Methods:

• Longitudinal monitoring of plasma concentrations of primidone and phenobarbitone in pregnant epileptic patients.
• Patients received constant doses of primidone (with or without other antiepileptic drugs) or phenobarbitone throughout pregnancy and the puerperium.
• Comparison of drug concentrations across different trimesters of pregnancy.

Main Results:

• A trend of increasing primidone plasma concentrations was observed during the second trimester of pregnancy.
• A significant decrease in phenobarbitone derived from primidone was noted concurrently.
• A trend towards lower plasma concentrations of administered phenobarbitone was confirmed.

Conclusions:

• Careful monitoring of primidone and its metabolite phenobarbitone is recommended during pregnancy and the puerperium.
• Pregnancy-induced metabolic changes affect primidone and phenobarbitone pharmacokinetics.
• Further investigation into the mechanisms underlying these pharmacokinetic discrepancies is warranted.